1-(3-chloropropyl)-6-fluoro-3,4-dihydro-1H-quinolin-2-one | 560082-98-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-(3-chloropropyl)-6-fluoro-3,4-dihydro-1H-quinolin-2-one
• 英文别名: 1-(3-chloro-propyl)-6-fluoro-3,4-dihydro-1H-quinolin-2-one；1-(3-chloropropyl)-6-fluoro-3,4-dihydroquinolin-2-one
• CAS: 560082-98-6
• 化学式: C₁₂H₁₃ClFNO
• 分子量: 241.693
• InChiKey: NXJCHOAZYUMUJZ-UHFFFAOYSA-N

物化性质

• 沸点：
  446.4±45.0 °C(Predicted)
• 密度：
  1.249±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(3-chloropropyl)-6-fluoro-3,4-dihydro-1H-quinolin-2-one 在 dimethyl sulfide borane 、 potassium carbonate 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 3.0h， 生成 1-(3-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)propyl)-6-fluoro-1,2,3,4-tetrahydroquinoline
  参考文献：
  名称：

  Rigid versus flexible anilines or anilides confirm the bicyclic ring as the hydrophobic portion for optimal σ₂ receptor binding and provide novel tools for the development of future σ₂ receptor PET radiotracers

  摘要：

  尽管它们的识别仍不确定，但σ2受体是肿瘤疾病诊断和治疗发展的有希望的靶点。

  DOI：

  10.1039/c6ra15783a
• 作为产物：
  描述：

  1,2,3,4-四氢喹啉 在 sodium tungstate (VI) dihydrate 、 二乙胺基三氟化硫 、 双氧水 、 sodium hydride 作用下， 以 甲醇 、 二氯甲烷 、 水 、 二甲基亚砜 、 mineral oil 为溶剂， 反应 2.0h， 生成 1-(3-chloropropyl)-6-fluoro-3,4-dihydro-1H-quinolin-2-one
  参考文献：
  名称：

  [EN] NOVEL HETEROCYCLIC CARBOXAMIDES AS M1 AGONISTS
  [FR] NOUVEAUX CARBOXAMIDES HÉTÉROCYCLIQUES COMME AGONISTES DE M1

  摘要：

  本发明涉及式(I)的新型M1激动化合物及其在治疗与精神分裂症等疾病相关的认知障碍以及在治疗其他通过胆碱能M1受体介导的疾病中的应用。

  公开号：

  WO2009106534A1

文献信息

• Tetrahydroquinoline analogues as muscarinic agonists
  申请人：Skjaerbaek Niels

  公开号：US20050209226A1

  公开（公告）日：2005-09-22

  The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.

  本发明涉及四氢喹啉化合物作为肌肉舒张剂；包含这些化合物的组合物；使用这些化合物抑制肌肉受体活性的方法；使用这些化合物治疗与肌肉受体相关的疾病状况的方法；以及使用这些化合物鉴定适合治疗的对象的方法。
• Muscarinic agonists
  申请人：Skjaerbaek Niels

  公开号：US20060199810A1

  公开（公告）日：2006-09-07

  The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.

  本发明涉及四氢喹啉化合物作为毒蕈碱受体激动剂；包含该化合物的组合物；使用该化合物抑制毒蕈碱受体活性的方法；使用该化合物治疗与毒蕈碱受体相关的疾病条件的方法；以及使用该化合物识别适合使用该化合物治疗的受试者的方法。
• TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS
  申请人：Skjaerback Niels

  公开号：US20090239903A1

  公开（公告）日：2009-09-24

  The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.

  本发明涉及四氢喹啉化合物作为肌肉型乙酰胆碱受体激动剂；包含该化合物的组合物；使用该化合物抑制肌肉型乙酰胆碱受体活性的方法；使用该化合物治疗与肌肉型乙酰胆碱受体有关的疾病状态的方法；以及使用该化合物识别适合接受治疗的受试者的方法。
• Discovery of <i>N</i>-{1-[3-(3-Oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): An Allosteric Muscarinic M₁ Receptor Agonist with Unprecedented Selectivity and Procognitive Potential
  作者：Anette G. Sams、Morten Hentzer、Gitte K. Mikkelsen、Krestian Larsen、Christoffer Bundgaard、Niels Plath、Claus T. Christoffersen、Benny Bang-Andersen

  DOI：10.1021/jm100697g

  日期：2010.9.9

  The discovery and structure activity relationship (SAR) of a series of allosteric muscarinic M, receptor agonists are described. Compound 17 (Lu AE51090) was identified as a representative compound from the series, based on its high selectivity as an agonist at the muscarinic M-1 receptor across a panel of muscarinic receptor subtypes. Furthermore, 17 displayed a high degree of selectivity when tested in a broad panel of G-protein-coupled receptors, ion channels, transporters, and enzymes, and 17 showed an acceptable pharmacokinetic profile and sufficient brain exposure in rodents in order to characterize the compound in vivo. Hence, in a rodent model of learning and memory, 17 reversed delay-induced natural forgetting, suggesting a procognitive potential of 17.
• Hit-to-lead investigation of a series of novel combined dopamine D2 and muscarinic M1 receptor ligands with putative antipsychotic and pro-cognitive potential
  作者：Anette Graven Sams、Krestian Larsen、Gitte Kobberøe Mikkelsen、Morten Hentzer、Claus Tornby Christoffersen、Klaus Gjervig Jensen、Kristen Frederiksen、Benny Bang-Andersen

  DOI：10.1016/j.bmcl.2012.05.048

  日期：2012.8

  We describe the discovery of a series of compounds based on 1-3-[4-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidin-1-yl]-propyl}-3,4-dihydro-1H-quinolin-2-one (3), showing combined D-2 receptor affinity and M-1 receptor agonism. Based on a strategy of controlling log P, we herein describe a hit-to-lead investigation with the aim of retaining the combined D-2/M-1 profile, while removing the propensity of the compounds to inhibit the hERG channel, as well as at obtaining acceptable pharmacokinetic properties. Although a SAR was evident for all four parameters in question, it was not possible to separate hERG channel inhibition and D-2 receptor affinity by this effort; whilst it was feasible to obtain compounds with M-1 receptor agonism, acceptable clearance, and weak hERG inhibition. (C) 2012 Elsevier Ltd. All rights reserved.